Takeda, Amylin to co-develop obesity drugs
TOKYO, Nov 2 (Reuters) - Japan's Takeda Pharmaceutical (4502.T) and U.S. Amylin Pharmaceuticals (AMLN.O) said on Monday they have agreed to co-develop drugs to treat obesity.
Amylin will receive a one-time up-front payment of $75 million from Takeda, the companies said in a joint statement. (Reporting by Taiga Uranaka)










